+41 91 682 20 40 info@elixi-int.com

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients

Bristol-Myers Squibb has announced results from pooled analyses of survival data from four studies in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were treated with Opdivo. In the pooled analysis of the four studies, 14% of all Opdivo-treated patients…

Read More